Impact of Arterial Hypertension on Doxorubicin-Based Chemotherapy-Induced Subclinical Cardiac Damage in Breast Cancer Patients

Vaitiekus, Domas; Muckienė, Gintarė; Vaitiekienė, Audronė; Maciuliene, Dainora; Vaičiulienė, Dovilė; Ambrazevičiūtė, Gretė; Sereikaitė, Liveta; Verikas, Dovydas; Jurkevičius, Renaldas; Juozaitytė, Elona

doi:10.1007/s12012-019-09556-3

Cited by 29 publications

(43 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adriamycin (ADR; doxorubicin) is a chemical therapy against cancer (cytotoxic or antineoplastic), prescribed to treat several human carcinomas, including ovarian and breast cancers [4,5]. The successful use of ADR has induced harmful effects, with cardiotoxicity being the most prominent, especially in patients administered large doses.…”

Section: Introductionmentioning

confidence: 99%

Betanin and Allicin Ameliorate Adriamycin-Induced Cardiotoxicity in Rats by Ameliorating Cardiac Ischemia and Improving Antioxidant Efficiency

Al-Thubiani

Abu-Zinadah²,

El-Aziz³

2021

JPRI

View full text Add to dashboard Cite

Aims: To investigate the protective effects of betanin and allicin against adriamycin (ADR)-induced cardiotoxicity. Study Design: Experimental animal model. Place and Duration of Study: King Abdul-Aziz University, Jeddah, Saudi Arabia; 10 days. Methodology: Adult female Wistar rats were allocated to the following groups (n = 10 per group): Control, received water, a standard diet for 10 days and i.p normal saline on day 8; ADR, intraperitoneal injection with 15 mg/kg ADR as a single dose on day 8; ADR+BE, betanin (20 mg/kg) administration followed by i.p. injection of ADR (15 mg/kg); ADR+ALL, allicin (20 mg/kg) administration followed by i.p. injection of ADR; and ADR+BE+ALL, equal volumes of betanin and allicin followed by ADR (15 mg/kg). Hemodynamic characteristics of the cardiovascular system and electrocardiography were evaluated. Blood samples were obtained to assess cardiac enzymes; cardiac homogenates were processed to analyze oxidative and antioxidant parameters and low-grade inflammatory indicators. Histopathological evaluation of heart tissues was also conducted. Results: Rats pre-administered betanin and allicin were protected from ADR-associated ischemia based on the significant (P < .05) shortening of QT, QTC interval, QRS, and T peak Tend interval compared with the ADR group. Betanin and allicin pre-treatment significantly decreased the ADR-induced elevated serum creatine kinase-MB and lactate dehydrogenase levels. ADR-elevated cardiac oxidative parameters, along with the serum concentrations of the tumor necrosis factor-alpha and the cardiac transforming growth factor-beta, were significantly inhibited by betanin and allicin. Histopathological findings confirmed the biochemical results. Betanin and allicin reduced ADR-induced heart damage by inhibiting several pathways, including those of oxidative stress and inflammation. Conclusion: Betanin and allicin may be promising cardioprotective agents owing to their antioxidant and cytoprotective properties and could thus be used as adjuvant treatment for cancer therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Betanin and Allicin Ameliorate Adriamycin-Induced Cardiotoxicity in Rats by Ameliorating Cardiac Ischemia and Improving Antioxidant Efficiency

Al-Thubiani

Abu-Zinadah²,

El-Aziz³

2021

JPRI

View full text Add to dashboard Cite

show abstract

“…In the American Society of Clinical Oncology guidelines, arterial hypertension, dyslipidaemia, coronary artery disease and age > 65 years are considered risk factors for cardiotoxicity induced by antiblastic therapy. Both animal and human studies highlighted the weight of arterial hypertension in inducing cardiotoxicity, particularly in ANT-based therapy protocols [123][124][125][126].…”

Section: Hypertension Cancer and Cardiovascular Diseasementioning

confidence: 99%

Redox Imbalances in Ageing and Metabolic Alterations: Implications in Cancer and Cardiac Diseases. An Overview from the Working Group of Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology (SIC)

et al. 2020

View full text Add to dashboard Cite

Metabolic syndrome (MetS) is a well established risk factor for cardiovascular (CV) diseases. In addition, several studies indicate that MetS correlates with the increased risk of cancer in adults. The mechanisms linking MetS and cancer are not fully understood. Several risk factors involved in MetS are also cancer risk factors, such as the consumption of high calorie-food or high fat intake, low fibre intake, and sedentary lifestyle. Other common aspects of both cancer and MetS are oxidative stress and inflammation. In addition, some anticancer treatments can induce cardiotoxicity, including, for instance, left ventricular (LV) dysfunction and heart failure (HF), endothelial dysfunction and hypertension. In this review, we analyse several aspects of MetS, cancer and cardiotoxicity from anticancer drugs. In particular, we focus on oxidative stress in ageing, cancer and CV diseases, and we analyse the connections among CV risk factors, cancer and cardiotoxicity from anticancer drugs.

show abstract

“…14 Comorbid conditions, such as cardiac diseases, arterial hypertension, diabetes, dyslipidemia, and renal failure, are also significant risk factors. 15,16 Patients treated with anthracyclines are five times more likely to have reduced left ventricular ejection fraction or develop HF compared with those treated with other non-anthracycline chemotherapy. 4 AIC can be acute or chronic, with acute cardiotoxicity occurring during the treatment or immediately afterward; this entails pericarditis-myocarditis and arrhythmias, which are both possibly reversible.…”

Section: Anthracyclines and Cardiotoxicitymentioning

confidence: 99%

“…Other factors, such as female sex, age above 60 years, pediatric population, and previous radiotherapy have also been associated with a higher risk of cardiotoxicity 14 . Comorbid conditions, such as cardiac diseases, arterial hypertension, diabetes, dyslipidemia, and renal failure, are also significant risk factors 15,16 …”

Section: Anthracyclines and Cardiotoxicitymentioning

confidence: 99%

Epigenetic Changes Associated With Anthracycline‐Induced Cardiotoxicity

Tantawy

Pamittan

Singh

et al. 2020

Clinical Translational Sci

View full text Add to dashboard Cite

Advances in cancer treatment have significantly improved the survival of patients with cancer, but, unfortunately, many of these treatments also have long‐term complications. Cancer treatment‐related cardiotoxicities are becoming a significant clinical problem that a new discipline, Cardio‐Oncology, was established to advance the cardiovascular care of patients with growing cancer populations. Anthracyclines are a class of chemotherapeutic agents used to treat many cancers in adults and children. Their clinical use is limited by anthracycline‐induced cardiotoxicity (AIC), which can lead to heart failure. Early‐onset cardiotoxicity appears within a year of treatment, whereas late‐onset cardiotoxicity occurs > 1 year and even up to decades after treatment completion. The pathophysiology of AIC was hypothesized to be caused by generation of reactive oxygen species that lead to lipid peroxidation, defective mitochondrial biogenesis, and DNA damage of the cardiomyocytes. The accumulation of anthracycline metabolites was also proposed to cause mitochondrial damage and the induction of cardiac cell apoptosis, which induces arrhythmias, contractile dysfunction, and cardiomyocyte death. This paper will provide a general overview of cardiotoxicity focusing on the effect of anthracyclines and their epigenetic molecular mechanisms on cardiotoxicity.

show abstract

Impact of Arterial Hypertension on Doxorubicin-Based Chemotherapy-Induced Subclinical Cardiac Damage in Breast Cancer Patients

Cited by 29 publications

References 24 publications

Betanin and Allicin Ameliorate Adriamycin-Induced Cardiotoxicity in Rats by Ameliorating Cardiac Ischemia and Improving Antioxidant Efficiency

Betanin and Allicin Ameliorate Adriamycin-Induced Cardiotoxicity in Rats by Ameliorating Cardiac Ischemia and Improving Antioxidant Efficiency

Redox Imbalances in Ageing and Metabolic Alterations: Implications in Cancer and Cardiac Diseases. An Overview from the Working Group of Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology (SIC)

Epigenetic Changes Associated With Anthracycline‐Induced Cardiotoxicity

Contact Info

Product

Resources

About